Introduction
The cytochrome P450s (CYPs) superfamily consists of a large number of haem-containing mono-oxygenases that play a pivotal role in the metabolism of many drugs and carcinogens [1] .
Much of the work carried out on the role of CYPs in xenobiotic metabolism has been done in vitro, and has yielded vital information on CYP regulation and function. However, extrapolation from in vitro data to in vivo pharmacokinetics requires additional factors such as route of administration, absorption, renal clearance and tissue-specific CYP expression to be considered [2] . A number of gene knock-out and transgenic mice have been developed to study the role of specific enzymes in xenobiotic metabolism [3, 4] and, although CYP knock-out mouse models have provided important data on the effect of a single CYP enzyme on chemical-induced genotoxicity and carcinogenesis [5] [6] [7] [8] [9] [10] , the functional redundancy inevitably found in the CYP gene superfamily makes it difficult to determine the in-vivo role of these enzymes in carcinogen metabolism as a whole [11] . To overcome these limitations a mouse line, HRN (Hepatic Cytochrome P450 Reductase Null), has been developed in which cytochrome P450 oxidoreductase (POR), the unique electron donor to CYPs is deleted specifically in hepatocytes, resulting in the loss of essentially all hepatic CYP function [12] . The HRN mouse can be used to establish the role of hepatic versus extra-hepatic xenobiotic metabolism and disposition [11, 13] .
Polycyclic aromatic hydrocarbons (PAHs), of which benzo[a]pyrene (BaP) is the most commonly studied and measured, are formed by the incomplete combustion of organic matter [14] .
They are widely distributed in the environment and human exposure to them is unavoidable. Many compounds characterised as PAHs are found in tobacco smoke condensate, although for nonsmokers, the principal route of exposure is through diet [15, 16] . A number of PAHs, including BaP, are mutagenic and carcinogenic, and they are widely believed to make a substantial contribution to the overall burden of cancer in humans [14, 16, 17] . BaP requires metabolic activation prior to reaction with DNA, which is an essential step in the mechanism by which BaP exerts its genotoxic effects [18] [19] [20] . The level of BaP-DNA adducts in cells is most likely the result of a balance between their formation and their loss through either DNA repair processes and/or apoptosis. Thus, BaP genotoxicity depends on various factors: (i) metabolic activation of BaP by phase I enzymes to reactive DNA binding species; (ii) detoxification of reactive BaP metabolites by both phase I and phase II enzymes; (iii) rate of repair of BaP-DNA adducts; and (iv) BaP-induced expression of genes such as those encoding enzymes involved in activation/detoxification or DNA damage response [10] .
Based on evidence primarily from in-vitro experiments, CYP1A1 and CYP1B1 are two of the most important enzymes in the metabolic activation of BaP, resulting in the formation of an epoxide that is then converted to a dihydrodiol by epoxide hydrolase [14, 19] . Further bioactivation by CYP1A1 and CYP1B1 leads to the formation of the ultimately reactive species, benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide (BPDE) that can react with DNA, forming adducts preferentially at guanine residues, namely 10-(deoxyguanosin-N 2 -yl)-7,8,9-trihydroxy-7,8,9,10-tetrahydrobenzo[a]pyrene (dG-N 2 -BPDE) [20] .
We observed recently that the carcinogen 3-nitrobenzanthrone, which is activated in vitro predominantly by cytosolic nitroreductases rather than microsomal POR [21] , formed DNA adducts in tissues of HRN and WT mice at similar levels [21] , whereas its metabolite 3-aminobenzanthrone, whose activation in vitro is primarily CYP-dependent [22] , formed significantly lower levels of adducts in the livers of HRN than of WT mice [23] . Moreover, we found that in HRN and WT mice treated with the antineoplastic agent ellipticine, which forms DNA adducts mediated by CYPs and peroxidases, levels of hepatic ellipticine-DNA adducts were up to 65% lower in HRN mice, confirming the importance of CYPs in the bioactivation of ellipticine in the liver [24] . In the present study we report the results of experiments on BaP activation by mouse hepatic microsomes and in various mouse organs using the HRN model, from which we draw contrasting conclusions on the role of CYPs in the genotoxicity of BaP in vivo and in vitro.
Materials and methods

Chemicals
BaP (>96%) was purchased from Sigma-Aldrich (St. Louis, MO). All other chemicals were of analytical purity or better.
Animal treatment
HRN (Por lox/lox + Cre ALB ) mice on a C57BL/6 background (CXR Bioscience Ltd., Dundee, UK) used in this study were derived as described previously [12] . Mice homozygous for loxP sites at the 
Preparation of microsomes
Hepatic microsomes from HRN and WT mice (group II), untreated or treated with BaP for 5 days as described above, were isolated as described previously [30] . Pooled microsomal fractions were used for further analyses.
Preparation of CYP1A1 and POR antibodies
Recombinant rat CYP1A1 protein was purified to homogeneity from membranes of Escherichia coli transfected with a modified CYP1A1 cDNA [31] . Rabbit liver POR was purified as described [32] . Leghorn chickens were immunized subcutaneously three times (with one week interval) with rat recombinant CYP1A1 and rabbit hepatic POR antigens (0.1 mg/animal) emulsified in complete 
Determination of CYP1A and POR enzymatic activity in hepatic microsomes
The hepatic microsomal samples were characterized for CYP1A activity using 7-ethoxyresorufin Odeetylation (EROD) activity [31, 33] . The activity of POR was measured as reported previously [34] .
Real-time quantitative PCR
Total RNA was isolated from livers of HRN and WT mice killed after 5 days (either untreated or treated with BaP; group II). Tissue (∼20 mg) was homogenized in 600 µl trizol (Invitrogen, UK).
After addition of chloroform (120 µl), samples were centrifuged for 20 minutes at >10,000g (4ºC), and the supernatant was mixed with 70% ethanol (600 µl). Total RNA was extracted using the Qiagen RNeasy Mini Kit protocol (RNeasy Mini Handbook, Qiagen, UK) as described [35] . Twostep reverse transcription-PCR was used to generate cDNA for relative quantitation analysis using real-time fluorescent PCR on an ABI PRISM 7900HT Sequence Detection System (Applied Biosystems, UK) performed as previously described [35] . To detect the modulated expression of selected target genes 20x Assays-On-Demand TM gene expression primers and probes (Applied Biosystems) were used (PTGS1-Mm00477214_m1, PTGS2-Mm00478374_m1, MPO-Mm00447885_m1). All PCR reactions were performed in triplicate and relative gene expression was calculated using the comparative threshold cycle (C T ) method as performed previously [35] .
Microsomal incubations
Incubation mixtures consisted of 50 mM potassium phosphate buffer (pH 7 
Inhibition studies
The following chemicals were used to inhibit the activation of BaP in mouse hepatic microsomes:
α-naphthoflavone (α-NF), which inhibits CYP1A1 and CYP1A2 [22, 37] ; ellipticine, which competes with CYP1A1 substrates, thus inhibiting efficiently CYP1A1-mediated oxidation of other substrates [30, 38] ; indomethacin, a selective inhibitor of PTGS [37] ; and α-lipoic acid, which inhibits POR [34] . Inhibitors were dissolved in 7.5 µl of methanol, to yield final concentrations of 0.1 mM in the incubation mixtures. Mixtures were then incubated at 37ºC for 10 min with NADPH prior to adding BaP, and then incubated for a further 90 min at 37ºC. After the incubation, DNA was isolated as mentioned above.
Results
DNA adduct formation in mice
DNA adduct formation in organs (liver, lung, forestomach, glandular stomach, kidney, bladder, spleen and colon) of HRN and WT mice treated i.p. with either a single dose or 5 daily doses of BaP was analysed by 32 P-postlabelling. On TLC the DNA adduct pattern consisted of a single spot with all organs from BaP-treated animals ( Figure 1A and 1B, inset), whereas no DNA adducts were detected in control animals (data not shown). The identity of the material in the adduct spots was determined by HPLC to be the reactive metabolite BPDE bound to the N 2 position of guanine (dG- DNA adduct levels were quantitated by both 32 P-postlabelling and by LC-MS/MS. Figure 3 shows the results of 32 P-postlabelling, in which it can be seen that after a single dose of BaP ( Figure   3A ) significantly higher levels of adducts (up to 2.6-fold) were formed in 5/7 of the extra-hepatic tissues (P<0.05) of the HRN mice that lack hepatic CYP activity. This difference was less evident after mice had received multiple doses of BaP ( Figure 3B ), when only 2 of the extra-hepatic tissues of HRN mice, lung and colon, had significantly more adducts than were found in WT mice. The greatest differences between HRN and WT mice, however, were found with liver DNA adducts.
After a single dose of BaP, adduct levels were 13.4-fold higher in HRN mice ( Figure 3A ), and the difference was 6.4-fold after multiple doses ( Figure 3B ) (P<0.01). Quantitation of hepatic dG-N 2 -BPDE levels by LC-MS/MS SRM revealed that DNA binding in HRN mice was up to 16.5-fold higher than in WT mice (see legend Figure 2 ). In the present study DNA adduct levels determined by LC-MS/MS SRM were generally 2−3-fold higher than those determined by TLC 32 Ppostlabelling, an observation which is consistent with previous results [29] .
BaP clearance in blood
The concentration of BaP in blood after i.p. treatment of HRN and WT mice with a single dose of BaP was determined using HPLC with fluorescence detection (Figure 4 ). Pharmacokinetic analysis revealed no statistically significant difference in any of the analysed parameters (e.g. clearance,
terminal half-life, AUC). As can be seen in Figure 4 the C max was slightly higher (around 1.25-fold)
in HRN relative to WT mice, but this difference was not statistically significant.
The effect of BaP on expression of hepatic biotransforming enzymes
Using Western blot analysis with polyclonal antibodies raised against CYP1A1, POR or PTGS, the protein expression levels of these enzymes were determined in hepatic microsomes isolated from HRN and WT mice from group II. Both CYP1A enzymes are constitutively expressed in livers of untreated HRN and WT mice, with HRN mice having marginally higher levels (1.4-fold) than WT mice ( Figure 5A ). Treatment with BaP led to 98-fold higher expression levels of CYP1A in livers of WT mice, but induced its levels 175-fold in HRN mice. The increase in CYP1A levels in these WT mice was associated with a strong increase in EROD activity, a measure of CYP1A enzyme activity ( Figure 5C ). EROD activity was also observed in HRN mice treated with BaP, but it was 3.4-fold lower than in WT mice treated with BaP, whereas no EROD activity was detectable in untreated HRN mice.
Hepatic POR expression was detected in WT mice, while as expected, its levels in HRN mice were very low, but still detectable, by immunostaining ( Figure 5B ). Hepatic POR levels in HRN mice were estimated to be less than 1.5% of the levels in WT mice ( Figure 5B ). POR activity measured with cytochrome c as a substrate was, however, not detectable in hepatic microsomes of HRN mice ( Figure 5D ). Surprisingly, the expression level of POR was also slightly induced in hepatic microsomes from mice treated with BaP ( Figure 5B ), where we found a 1.6-and 2.9-fold increase in WT and HRN mice, respectively. It is noteworthy that POR activity was detectable in HRN mice treated with BaP ( Figure 5D ). However, no protein expression of PTGS1 and PTGS2
was detectable in hepatic microsomes under any of the experimental conditions used (data not shown).
Besides the evaluation of the effects of BaP on hepatic CYP-related enzymes, modulation of PTGS and myeloperoxidase (MPO) mRNA expression by BaP in these mice was also investigated.
Total RNA was isolated from frozen livers of group II mice and the relative amounts of PTGS1, PTGS2 and MPO mRNAs were measured by real-time PCR. No expression of PTGS2 and MPO was observed and no BaP-induced change in expression of PTGS1 mRNA was detectable under the experimental conditions used (data not shown). No differences in PTGS1 mRNA levels were observed between WT and HRN mice (data not shown).
Activation of BaP by hepatic microsomes
We determined DNA adduct formation by BaP in in vitro incubations with calf thymus DNA in the presence of microsomes isolated from livers of HRN and WT mice from group II. Hepatic microsomes from both mice strains were capable of activating BaP to form DNA adducts ( Figure 6 ).
Using TLC 32 P-postlabelling one major DNA adduct spot was detected, corresponding to the one found in all the BaP-treated mouse tissues (compare Figure 1 As shown in Figure 6 , the formation of BaP-DNA adducts was stimulated by NADPH and NADH. DNA adduct formation catalysed by hepatic microsomes from mice pretreated with BaP was generally higher ( Figure 6B ) than with hepatic microsomes isolated from untreated mice ( Figure 6A ). NADPH, a cofactor for CYP-dependent oxidation of BaP, was the most effective cofactor in both systems. DNA adduct levels were up to 7-fold higher after activation with hepatic microsomes isolated from livers of WT than those from HRN mice. 
Discussion
CYP1A1 is believed to be one of the major enzymes responsible for the metabolic activation of BaP in organisms [14, 19] . CYPs comprise a large family of subfamilies and isoenzymes showing considerable redundancy and overlapping substrate specificity [1] . To examine the effect of CYPs as a whole on hepatic BaP metabolism and metabolic activation we utilized the HRN mouse [12] , which carries a deletion of the POR gene specifically in the liver, and thus lack CYP function in hepatocytes [11] . A limited number of treatments of mice with the dose used in this study, 125 mg/kg body weight, is carcinogenic [40] and induces mutagenicity in multiple organs [41] .
In the present study we showed the specific role of hepatic CYP enzymes in the activating pathways of BaP in vitro. BaP-DNA adduct formation was strongly dependent on the catalytic activities of POR present in the mouse hepatic microsomes assayed. This conclusion was further supported by the inhibition of BaP-DNA adduct formation with α-lipoic acid, a specific inhibitor of POR [34] . Using specific CYP inhibitors, namely α-NF and ellipticine [33, 38] , most of the CYP- This, in combination with the finding that BaP is a strong CYP inducer maybe also in otherwise not very active non-parenchymal cells, may explain these in vitro findings. The increase in DNA adduct formation upon pre-treatment with BaP catalysed by microsomes from WT mice is only 28.3-fold, while 50.5-fold in HRN mice indicating that another BaP inducible activating mechanism, independent of POR is responsible for BaP activation in vitro in these mice. Similarly, residual in vitro metabolism of the anticancer drug cyclophosphamide was observed in incubations using hepatic microsomes isolated from HRN mice [13] . Moreover, a recent study showed that pulmonary
CYPs play a major role in 4-(methylnitrosamino)-1-(3-pyridyl)-1-butone (NNK)-induced lung
tumours and that the number of NNK-induced lung tumours were reduced in pulmonary POR-null mice but were increased in hepatic POR-null mice relative to WT control [42] . However, lung tumours in pulmonary POR-null mice were positive for POR expression because POR deletion occurred in only a portion of the Clara cells and the alveolar type II epithelial (AECII) cells, indicating that the NNK-induced tumours were derived from POR-expressing AECII cells.
Another explanation could be the induction of metabolising enzymes other than CYPs. In hepatic microsomes isolated from BaP-treated HRN mice DNA adduct formation was observed even without the addition of BaP suggesting that BaP and/or its metabolites can bind to hepatic microsomal membranes, but it is subsequently released to react with DNA during the in vitro incubation. The latter effect was much more pronounced in hepatic microsomes isolated from HRN mice, suggesting the induction of metabolising enzymes in the latter microsomes. BaP is not only a good substrate for CYP1A1 and CYP1B1, but also for PTGS2 [43] . When we used arachidonic acid, a cofactor for PTGS2, in hepatic microsomes isolated from mice treated with BaP, no increase in BaP-DNA adduct formation was observed. This is consistent with no detectable PTGS proteins in hepatic microsomes of either mouse strain.
Previous studies demonstrated that for a genotoxin activated by a CYP-independent mechanism, 3-nitrobenzanthrone, DNA adduct formation in mouse tissues was the same in HRN indeed detect more adducts in extra-hepatic tissues, we also found that the levels in liver were vastly elevated, not reduced.
Our studies on the consequences of organ-specific loss of all CYP function bear comparison with other studies on the systemic loss of function, or abrogation of induction, of specific CYPs.
Administration of a high dose of BaP i.p. to Cyp1a1(-/-) mice resulted in slower clearance and higher adduct levels (4-fold) in liver than in Cyp1a1(+/-) mice [44] . Repeated high doses were less toxic to the homozygous knock-out mice than to the heterozygotes. The results were interpreted to indicate that absence of CYP1A1 protects the intact animal from BaP-mediated liver toxicity by decreasing the formation of large amounts of toxic metabolites, while the slower metabolic clearance of BaP resulted in greater formation of BaP-DNA adducts in the livers of the Cyp1a1(-/-) mice [44] . Conversely, BaP was more toxic to Cyp1a1(-/-) mice than to Cyp1a1(+/+) WT mice
given by oral administration [10] . The rate of clearance was still slower (4-fold) in the knock-out mice, and higher levels of DNA adducts were observed in liver, spleen and bone marrow, but not in small intestine, accompanied by qualitative differences in the DNA adduct patterns between the two genotypes. Combined studies with Cyp1a1(-/-) and Cyp1b1(-/-) single knock-out and Cyp1a1/1b1(-/-) double knock-out mice administrated BaP orally essentially mirrored these findings [45] . In the present study we chose i.p. injection as administration route to achieve a high induction of hepatic BaP metabolism. However, although we found much higher DNA adduct levels in the livers of HRN than in WT mice, we found no statistically significant difference in BaP pharmacokinetics (e.g. clearance, terminal half-life, and AUC) in HRN relative to WT mice.
BaP induces CYP1A1 through binding to the aryl hydrocarbon receptor (AhR), a transcription factor that also regulates the expression of a number of other phase I and phase II xenobiotic metabolising enzyme genes. Mice that lack AhR have been found to be refractory to BaP carcinogenesis after the compound was administered topically or subcutaneously, a finding that was interpreted as demonstrating that AhR is involved in BaP carcinogenesis and in converting BaP to its active metabolite(s) [46] . However, when BaP was administered i.p. to AhR(-/-) mice, total BaP-DNA adduct formation was at similar levels as in WT mice, although the levels of individual postlabelling adduct spots varied [47] . In another study in which BaP was given by gavage to AhR(-/-) mice, liver adduct levels were significantly higher than in the WT mice [48] . The authors observed slower clearance of BaP in the knock-out mice, as was also observed by Uno and coworkers in the Cyp1a1(-/-) mice [10] and suggested that this may explain, at least partly, the increase in DNA adduct levels. However, our present study with HRN mice did not indicate slower clearance of BaP, thereby excluding such an explanation for the high liver DNA adducts that we detected, if it can be assumed that concentrations of BaP in blood reflect tissue concentrations. The formation of BaP-DNA adducts in incubations of hepatic microsomes from BaP-pretreated mice, without the addition of BaP, suggests some BaP accumulated in the livers of the HRN mice. While the in vivo studies together represent a variety of doses, durations of treatment and routes of administration, overall the impression is that the function of hepatic CYPs is to detoxify BaP, not to activate it, which is in direct contrast to the general assumption from in vitro studies which point to metabolic activation of BaP by this enzyme system.
The mechanism by which DNA-binding species were generated in liver from BaP in the present study is not known, but it is clear that the process did not involve generation of a different reactive species from that formed in WT mice. The DNA adduct patterns obtained by 32 Ppostlabelling were the same for the knock-out and WT mice for liver and, indeed, for extra-hepatic tissues, and the unequivocal identification of the major adduct as being the product of the reaction of BPDE with guanine residues in DNA was confirmed by MS. Previously, a very good correlation was obtained between BaP-DNA adduct determination by 32 P-postlabelling and LC-MS/MS SRM [29] . If, as is suggested by our study and those of other investigators [47, 48] , metabolic activation of BaP in vivo is mediated by CYP-independent and/or AhR-independent pathways, it is apparent from our own studies, if not from others, that the end result, i.e. the nature of the DNA adducts formed, is the same. Besides differences in CYP enzyme activities the above-mentioned PTGS2 may be of importance to explain the high BaP-DNA adduct levels found in livers of HRN mice, which lack almost all POR-mediated CYP-catalysed bioactivation. However, we did not find any differences neither in PTGS2 protein levels nor PTGS2 gene expression. Therefore, the role of other,
as-yet-unidentified, BaP-activating enzymes awaits further investigation.
It is noteworthy that microarray gene expression technology previously showed that the absence of POR in the liver, and thus hepatic CYP function, appears to result only in minor compensatory changes in the expression of genes encoding for phase I and phase II xenobioticmetabolising enzymes in untreated animals [49] . Among them only the glutathione S-transferases (GSTs), namely GSTM2 and GSTM3, showed significant induction. Diol epoxides such as BPDE are detoxified by GSTs, in particular GSTM1 [19] , and the ratio between CYP1A1 and GST enzyme activities has been described as a critical determinant of the target dose of reactive DNAbinding BPDE [50] . As epidemiological studies indicate a dependence of BaP-DNA adduct levels on the CYP1A1 and GSTM1 genotype [50] , the expression of GSTs may also need consideration to explain the increased BaP-induced DNA adduct formation in HRN mice.
Numerous studies have shown that BaP is metabolised by CYPs to phenols, quinones, epoxides and arene oxides [19] . In mouse hepatoma Hepa1c1c7 cells, which express inducible CYP1A1, 3-hydroxybenzo[a]pyrene was the major metabolite formed after exposure to BaP [26] and this BaP metabolite is known to inhibit mutagenesis and tumourigenesis [51] . Thus, although the metabolites of BaP were not determined in the present study, it is tempting to speculate that increased CYP-catalysed formation of 3-hydroxybenzo[a]pyrene in WT mice may inhibit BaPinduced DNA adduct formation to a greater extent than in HRN mice. This would be the case especially after BaP induced CYP activity, which was much higher in livers of WT than in HRN mice.
In general, i.p. administration results in the uptake of BaP by mesenteric veins and lymphatic system that go directly to the liver, bypassing the gastrointestinal tract. It was pointed out previously that important pharmacokinetic differences depend on the route of administration [10] .
After oral administration BaP uptake would be via the gastrointestinal tract and then to the liver.
Therefore, it would be interesting to dissect the first pass elimination further by using a gastrointestinal tract-and liver-specific conditional POR knock-out mouse line. Recently, a variant on the HRN mouse line (Por lox/lox /Cre CYP1A1 ) has been developed in which POR can be deleted conditionally in the liver and gastrointestinal tract using the rat CYP1A1 promoter to drive Cre recombinase expression [52] . Using this line, administration of the CYP1A1 inducers tetrachlorodibenzo-p-dioxin or β-NF results in both hepatic and gastrointestinal deletion of POR, 
